Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20879474 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2DPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL500460 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2DPP4ALDH1A1MAPTPTGS1 | |
| Hydrochloric Acid SCHEMBL29398329 | 0.97 | SMN1; SMN2 (0.41) | SMN1; SMN2DPP4ALDH1A1MAPTPTGS1 | |
| Hydrochloric Acid SCHEMBL1705950 | 0.97 | SMN1; SMN2 (0.41) | SMN1; SMN2DPP4ALDH1A1MAPTPTGS1 | |
| Hydrochloric Acid SCHEMBL737492 | 0.97 | SMN1; SMN2 (0.41) | SMN1; SMN2DPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL3015800 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2DPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL16147546 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2DPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL255215 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2DPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL16821022 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2DPP4ALDH1A1MAPTPTGS1 | |
| SCHEMBL7540176 | 0.81 | ALDH1A1 (0.39) | DPP4ALDH1A1MAPTPTGS1FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215076-A2 | COMPOUNDS THAT INHIBIT PROTEASE CATHEPSIN S AND HCV REPLICATION | Virobay, Inc. (US) | 2010-08-11 | — | — | EP | claimed |
| US-20090270415-A1 | COMPOUNDS THAT INHIBIT PROTEASE CATHEPSIN S AND HCV REPLICATION | VIROBAY, INC. (US) | 2009-10-29 | — | — | US | claimed |
| WO-2009055467-A2 | COMPOUNDS THAT INHIBIT PROTEASE CATHEPSIN S AND HCV REPLICATION | VIROBAY, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-1250340-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
| CN-1310179-A | Oxamide being as IMPDH inhibitor | HOFFMANN LA ROCHE (CH) | 2001-08-29 | — | — | CN | disclosed |
| WO-2001046199-A1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-0712390-B1 | SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS | CELLTECH THERAPEUTICS LTD (GB) | 1998-12-09 | — | — | EP | disclosed |
| US-5827890-A | ANGIOGENESIS INHIBITORS | CELLTECH THERAPEUTICS LTD. (GB) | 1998-10-27 | — | — | US | disclosed |
| WO-1995004033-A1 | SUCCINAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS GELATINASE AND COLLAGENASE INHIBITORS | CELLTECH LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270415-A1 | COMPOUNDS THAT INHIBIT PROTEASE CATHEPSIN S AND HCV REPLICATION | CTSS, CTSV, CTSE | SMN1; SMN2 3554/4885DPP4 120/4885ALDH1A1 3330/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | SMN1; SMN2 3983/4885DPP4 3928/4885ALDH1A1 2257/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | SMN1; SMN2 881/4885DPP4 267/4885ALDH1A1 3360/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | SMN1; SMN2 208/4885DPP4 4074/4885ALDH1A1 3623/4885 |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ABCC1, ABCB11, ABCB1 | SMN1; SMN2 4221/4885DPP4 1737/4885ALDH1A1 264/4885 |
| US-11771695-B2 | Cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | SMN1; SMN2 2187/4885DPP4 4488/4885ALDH1A1 2692/4885 |
| US-12109219-B2 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | SMN1; SMN2 4018/4885DPP4 4760/4885ALDH1A1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.